MannKind | MNKD - Interest Expense On Debt


MannKind reported $10.58M in Interest Expense on Debt for its fiscal quarter ending in September of 2026.





Interest Expense On Debt Change Date
Adma Biologics USD 3.42M 1.32M Jun/2026
BioCryst Pharmaceuticals USD 21.71M 7.58M Jun/2026
Eli Lilly USD 316M 201.3M Sep/2026
Halozyme Therapeutics USD 6.04M 457K Sep/2026
Insmed USD 20.41M 1.57M Sep/2026
Karyopharm Therapeutics USD 12.55M 66K Mar/2026
MacroGenics USD 4.4M 493K Jun/2026
MannKind USD 10.58M 4.24M Sep/2026
Merck USD 525M 46M Jun/2026
Minerva Neurosciences USD 2.31M 60K Jun/2024
Novavax USD 5.82M 342K Dec/2025
Pfizer USD 662M 5M Sep/2026
Sanofi EUR 222M 65M Sep/2026
Xencor USD 4.11M 3.24M Sep/2026